Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ...

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a ...

Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple early-stage ...

The results of South San Francisco-based Freenome Holdings Inc.’s 42,000-person study won’t be released until the second half of this year. But leaders of the privately held company and its ...

Freenome said the money would be used for a validation study and would then submit an application for its colorectal cancer screening test to both the U.S. Food and Drug Administration (FDA) and ...

Freenome Holdings Inc. has raised $270 million to pursue U.S. regulatory approval of a blood test to detect colorectal cancer, part of a push by molecular-testing companies to enable earlier ...